What is Tectin™?
Tectin™ is WEX's first lead product in the field of analgesia for the treatment of inadequately controlled cancer pain.
How can Tectin™
be administered?
Tectin™
can be administered as an intramuscular and as a subcutaneous
injection
Will Tectin™ be available on prescription?
Yes, due to the safety aspect, WEX will provide the product through clinics, hospitals and doctors only.
What advantages does Tectin™ have compared to other treatments?
To date, clinical trials have shown to have fast onset time, long duration, no constipation effects and clarity of mind as the most obvious advantages.
What is the development
status of Tectin™?
The Phase IIa
result showed Tectin™ to be meaningful as it relieved
chronic pain in 71% of cancer pain patients. The Company has recently terminated its Canadian Phase IIb/III trial after receiving an unfavourable interim analysis and is now reviewing the data to determine the next course of action. Tectin™ has also been cleared for a severe non-malignant
chronic pain study in Canada and has begun its Chinese Phase
II analgesic study.